DFTX — Definium Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Definium Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 134 | 142 | 99.7 | 274 | 412 |
| Prepaid Expenses | |||||
| Total Current Assets | 137 | 146 | 104 | 282 | 419 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 164 | 170 | 125 | 302 | 440 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 10.4 | 17.9 | 32.2 | 38.8 | 66.7 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 12.3 | 19.1 | 46.4 | 60.7 | 108 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 152 | 151 | 78.1 | 241 | 332 |
| Total Liabilities & Shareholders' Equity | 164 | 170 | 125 | 302 | 440 |
| Total Common Shares Outstanding |